Date & Time
January 24, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval
About the Event
Solving a difficult problem requires a smart team with experience. That’s just what Assembly Bio (NASDAQ: ASMB) has put together to take on the challenge of curing Hepatitis B.
The Hepatitis B virus (HBV) infects 270 million people globally and complications caused by HBV kill close to 1 million people per year. Assembly Bio CEO, Dr. John McHutchison is the former Chief Science Officer at Gilead where he led the successful filing for curative treatment for Hepatitis C. Joining him is a team with over 80 years of experience working on developing treatments for HCV, HIV, and HBV. In addition to an experienced executive team, the company’s board of directors includes Nobel Laureate, Sir Michael Houghton, PhD.
Join this webinar to hear from the Dr. McHutchison as he discusses the company’s three tiered strategic approach to curing HBV and the major inflection points that are coming this year and next.